參考資料

Roche

參考資料

  1. National Cancer Institute. Cancer Screening [Internet]. U.S: National Institutes of Health; 2015 [Updated: August 19, 2020].  Available from: https://www.cancer.gov/about-cancer/screening/patient-screening-overview-pdq
  2. National Cancer Institute. Cancer Screening [Internet]. U.S: National Institutes of Health; 2015 [Updated: December 23, 2015].  Available from: https://www.cancer.gov/about-cancer/causes-prevention/risk
  3. National Cancer Institute. Cancer Screening [Internet]. U.S: National Institutes of Health; 2019 [Updated: July 17, 2019].  Available from: https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis
  4. National Cancer Institute. Cancer Screening [Internet]. U.S: National Institutes of Health; 2019 [Updated: July 17, 2019].  Available from: https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis
  5. National Cancer Institute. Genetic Testing for Inherited Cancer Susceptibility Syndromes [Internet]. U.S: National Institutes of Health; 2019 [Updated: March 15, 2019].  Available from: https://www.cancer.gov/about-cancer/causes-prevention/genetics/genetic-testing-fact-sheet#what-is-genetic-testing
  6. National Cancer Institute. Cancer Screening [Internet]. U.S: National Institutes of Health; 2021 [Updated: March 12, 2021].  Available from: https://www.cancer.gov/about-cancer/screening/screening-tests
  7. National Cancer Institute. Lung Cancer Screening (PDQ®)–Patient Version[Internet]. U.S: National Institutes of Health; 2021 [Updated: July 30, 2021].  Available from:https://www.cancer.gov/types/lung/patient/lung-screening-pdq
  8. National Cancer Institute. Breast Cancer Screening (PDQ®)–Patient Version[Internet]. U.S: National Institutes of Health; 2021 [Updated: August 4, 2021].  Available from:https://www.cancer.gov/types/breast/patient/breast-screening-pdq
  9. National Cancer Institute. HPV and Pap Testing[Internet]. U.S: National Institutes of Health; 2021 [Updated: December 20, 2019].  Available from:https://www.cancer.gov/types/cervical/pap-hpv-testing-fact-sheet
  10. American Society of Clinical Oncology (ASCO). Cervical Cancer: Introduction [Internet].Conquer Cancer ® The ASCO Foundation; 2020. Available from: https://www.cancer.net/cancer-types/cervical-cancer/introduction
  11. American Society of Clinical Oncology (ASCO). Types of Oncologists [Internet].Conquer Cancer ® The ASCO Foundation; 2020. Available from:https://www.cancer.net/navigating-cancer-care/cancer-basics/cancer-care-team/types-oncologists
  12. What does a radiologist do? Radiological Society of North America, Inc. (RSNA). February, 08, 2021. Available from: https://www.radiologyinfo.org/en/info/article-your-radiologist
  13. The Pathology Report. CancerQuest: Emory University. 2021 Dec 14. Available from: https://www.cancerquest.org/patients/detection-and-diagnosis/pathology
  14. The Pathology Report. CancerQuest: Emory University. 2021 Dec 14. Available from: https://www.cancerquest.org/patients/detection-and-diagnosis/pathology
  15. European Society of Surgical Oncology(ESSO). What is Surgical Oncology ? Available from: https://www.essoweb.org/what-is-surgical-oncology/
  16. American Society of Clinical Oncology (ASCO). The Genetics of Cancer [Internet].Conquer Cancer ® The ASCO Foundation; 2020. Available from: https://www.cancer.net/navigating-cancer-care/cancer-basics/genetics/genetics-cancer
  17. Stratton, M. R., Campbell, P. J., Futreal, P. A. The cancer genome. Nature. 2009. 458(7239):719–724.
  18. 2014 Nature Education. Genetic Mutation. Available from: https://www.nature.com/scitable/topicpage/genetic-mutation-441/
  19. BRAF (V-raf Murine Sarcoma Viral Oncogene Homolog B)：鼠類肉商濾過性毒菌致癌同源體;
    EGFR (Epidermal Growth Factor Receptor)：表皮生長因子受體；
    HER2 (Human Epidermal Growth Factor Receptor 2)：人類表皮生長因子受體二型;
    ALK (Anaplastic Lymphoma Kinase)：間變性淋巴瘤激酶
  20. Nature Education. Genetic mutation. Nature Education 1(1):187. Available at: https://www.nature.com/scitable/topicpage/genetic-mutation-441/
  21. Chinese Society of Clinical Oncology, Expert Committee on Non-small Cell Lung Cancer. Zhongguo fei ai za zhi = Chinese journal of lung cancer vol. 23,9 (2020): 741-761. doi:10.3779/j.issn.1009-3419.2020.101.45
  22. F. Hoffmann-La Roche Ltd. Diagnostics in oncology. 5.13.2022. Available from: https://www.roche.com/solutions/focus-areas/oncology/diagnostics-in-oncology
  23. Pinsky P. F. (2015). Principles of Cancer Screening. The Surgical clinics of North America, 95(5), 953–966. https://doi.org/10.1016/j.suc.2015.05.009
  24. Pinsky P. F. (2015). Principles of Cancer Screening. The Surgical clinics of North America, 95(5), 953–966. https://doi.org/10.1016/j.suc.2015.05.009
  25. American Society of Clinical Oncology (ASCO). Biopsy [Internet].Conquer Cancer ® The ASCO Foundation; 2020. Available from: https://www.cancer.net/navigating-cancer-care/diagnosing-cancer/tests-and-procedures/biopsy
  26. Konigorski S, Yilmaz YE, Pischon T. Comparison of single-marker and multi-marker tests in rare variant association studies of quantitative traits. PLoS One. 2017;12(5):e0178504. Published 2017 May 31.
  27. Dhaval Shah, MD et al. Hotspot Testing Versus Next-Generation Sequencing for NSCLC. Oct 23, 2017. Available from: https://connection.asco.org/magazine/current-controversies-oncology/hotspot-testing-versus-next-generation-sequencing-nsclc
  28. Dong, Ling et al. “Clinical Next Generation Sequencing for Precision Medicine in Cancer.” Current genomics vol. 16,4 (2015): 253-63. doi:10.2174/1389202915666150511205313
  29. FDA. SUMMARY OF SAFETY AND EFFECTIVENESS DATA (SSED). Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf
  30. Premarket Approval (PMA) [Internet]. U.S. Food and Drug Administration; 2017 Dec 15. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p170019
  31. FoundationOne CDx. Technical Information. Updated as Nov 2020.
  32. Frampton GM et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotech 2013,31(11): 1023-33.
  33. FoundationOne Liquid CDx. FDA approval, Aug 2020. Available at: https://www.foundationmedicine.com/press-releases/445c1f9e-6cbp-488b-84ad-5f133612b721  (AccessedDec2020)
  34. Foundation One Liquid CDx. Technical Information. Updated as Nov 2020.9.
  35. Foundation One HEME, technical information
  36. Zhao, P., Li, L., Jiang, X. et al. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. J Hematol Oncol 12, 54 (2019). https://doi.org/10.1186/s13045-019-0738-1
  37. Chalmers, Z.R., Connelly, C.F., Fabrizio, D. et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 2017; 9, 34.
  38. Ilié, M., & Hofman, P. Pros: Can tissue biopsy be replaced by liquid biopsy?. Translational lung cancer research 2016; 5(4):420–423.
  39. Ilié, M., & Hofman, P. Pros: Can tissue biopsy be replaced by liquid biopsy?. Translational lung cancer research 2016; 5(4):420–423.
  40. Ilié, M., & Hofman, P. Pros: Can tissue biopsy be replaced by liquid biopsy?. Translational lung cancer research 2016; 5(4):420–423.
  41. Sholl, L. M., Aisner, D. L., Allen, T. C., et al. Liquid Biopsy in Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society. Archives of pathology & laboratory medicine 2016; 140(8):825–829.
  42. Foundation One HEME, technical information
  43. Jørgensen J. T. Companion and Complementary Diagnostics: Clinical and Regulatory Perspectives. Trends in cancer 2016;2(12):706–712.
  44. What is cancer treatment tailored to gene mutations? Chugai Pharmaceutical Co., Ltd. 2020 May. Available from: https://gan-genome.jp/treat/typical.html
  45. Alexandrov, Ludmil B et al. Signatures of mutational processes in human cancer. Nature vol. 500,7463 (2013): 415-21. doi:10.1038/nature12477
  46. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12(2):175-180. doi:10.1016/S1470-2045(10)70087-5
  47. Bruce E. Johnson et al. A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC). 2013 ASCO Annual Meeting: abstract 8019.
  48. Jordan EJ, Kim HR, Arcila ME, et al. Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer Discov. 2017;7(6):596-609. doi:10.1158/2159-8290.CD-16-1337
  49. FoundationOne®CDx [Internet]. Foundation Medicine; Companion Diagnostic Indications. Available from: https://www.foundationmedicine.com/test/foundationone-cdx
  50. 腫瘤突變負荷(Tumor mutation burden, TMB)是每一百萬個鹼基（構成DNA及基因的基本單位)中排序錯誤(如置換、播入、飲失）的總數；
    微衛星(Microsatellite)是基因體中一些短而重覆的序列。
    微衛星不穩定性高(Microsatellite instability-high， MSI-H)是指微街星的序列出現鐠誤，成因是由於細胞的DNA錯配修復功能有缺陷：因此，微衛星不穩定性高亦反映這腫瘤很容易發生基因突變而不能被修復；
    腫瘤分數比例(Tumor fraction）是血液樣本中的循環腫瘤DNA (CtDNA)估計值，代表佔有總腫瘤負荷的百分率。
  51. Schwaederle, M., Zhao, M., Lee, J. J., et al.Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015; 33(32):3817–3825.
  52. Nathan A. Pennell, Alex Mutebi, Zheng-Yi Zhou, et al. Journal of Clinical Oncology 2018 May;36(15):9031-9031.
  53. The Why, When, and How of Getting a Second Opinion on Your Medical Diagnosis [Internet]. MEDIFIND.  Available from: https://www.medifind.com/news/post/second-opinion
  54. Aykan, N. F., & Özatlı, T. Objective response rate assessment in oncology: Current situation and future expectations. World journal of clinical oncology, 2020 11(2), 53–73. https://doi.org/10.5306/wjco.v11.i2.53
  55. Harvey RD, Adams VR, Beardslee T, Medina P. Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings. J Oncol Pharm Pract. 2020;26(6):1461-1474. doi:10.1177/1078155220931926
  56. Patient Doctor Discussion Guide [Internet]. Foundation Medicine; Companion Diagnostic Indications. Available from: https://assets.ctfassets.net/w98cd481qyp0/36LcH5nyKdlmxcw8KfjkU8/88eeaf0677151ffd5abb5f2ba0cd313a/Doctor_Discussion_Guide.pdf
  57. Patient FAQs [Internet]. Foundation Medicine; Companion Diagnostic Indications. Available from: https://www.foundationmedicine.com/faq/patient-faqs